Core Insights - Clear Medical (01406) reported a revenue of approximately HKD 85 million for the half-year ending in the fiscal year 2026, representing a slight decline of less than 3% compared to the same period last year [1] Group 1: Financial Performance - The company's revenue for the half-year period was approximately HKD 85 million, showing a minor decrease of less than 3% year-on-year [1] - The decline in revenue was attributed to extreme weather conditions that caused the closure or severe disruption of the company's clinics in Hong Kong for eight days during July to September [1] Group 2: Business Challenges - Negative media coverage stemming from allegations made by a former director may have adversely affected the company's business in recent months [1] Group 3: Technological Advancements - The company has strengthened its technological leadership in the Hong Kong ophthalmology market through an exclusive partnership with Johnson & Johnson to introduce the new generation refractive surgery technology, SILK [1] - The SILK technology utilizes low-energy, ultra-precise femtosecond laser pulses, effectively reducing corneal tissue and nerve damage, leading to faster recovery and better postoperative outcomes [1] - Clear Medical plans to promote the SILK technology in the fourth quarter of 2025, being the first and only institution in Hong Kong to offer this technology [1]

Core Viewpoint - Clear Medical (01406) reported a revenue of approximately HKD 85 million for the first half of the fiscal year ending 2026, reflecting a slight decline of less than 3% compared to the same period last year due to adverse weather conditions and negative media coverage [1] Financial Performance - The company achieved revenues of about HKD 85 million, which is a minor decrease of less than 3% year-on-year [1] - The Hong Kong clinics experienced operational disruptions for eight days from July to September due to extreme weather conditions [1] Business Developments - The company has strengthened its technological leadership in the Hong Kong ophthalmology market through an exclusive partnership with Johnson & Johnson to introduce the new generation refractive surgery technology SILK™ [1] - SILK™ technology utilizes low-energy, ultra-precise femtosecond laser pulses to minimize corneal and nerve tissue damage, leading to faster recovery and improved postoperative outcomes [1] - Clear Medical plans to promote the SILK™ technology in the fourth quarter of 2025, being the first and only institution in Hong Kong to offer this technology [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CLARITY MEDICAL GROUP HOLDING LIMITED 清晰醫療集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1406） (1)業務營運及復牌狀況季度更新； 及 (2)繼續暫停買賣 本公告乃由清晰醫療集團控股有限公司（「本公司」，連同其附屬公司統稱「本集 團」）根據香港聯合交易所有限公司（「聯交所」）《證券上市規則》（「上市規則」）第 13.09(2)(a)條及第13.24A條以及香港法例第571章《證券及期貨條例》第XIVA部項 下的內幕消息條文（定義見上市規則）而作出。 茲提述(i)本公司日期為二零二五年五月三十日有關聯交所發出復牌指引（「首次復 牌指引」）的公告；(ii)本公司日期為二零二五年六月三十日有關聯交所發出額外 復牌指引（連同首次復牌指引統稱「復牌指引」）的公告；及(iii)本公司日期為二零 二五年七月十四日有關提供其業務營運及復牌狀況季度更新的公告 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 清晰醫療集團控股有限公司 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01406 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.01 HKD | | 50,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.01 HKD | | 50,000,000 | 本月底法定/註冊股本總額： HKD 5 ...

Core Viewpoint - Clear Medical (01406) is facing a lawsuit initiated by former executive director Xie Weiye, following his removal from the board on August 1, 2025, and subsequent dismissal at a special shareholders' meeting on September 23, 2025 [1][2]. Group 1 - The lawsuit involves a request for the court to approve Xie Weiye to represent the company in legal actions against seven potential defendants, including current and former directors [2]. - The court is also being asked to appoint a receiver and manager for the company until the legal matters are resolved, as well as to appoint an independent party to investigate the company's financial status [2]. - The claims against the potential defendants include issues related to the acquisition of shares by Innovative Vision Inc, executive compensation, agreements with United Orion Advisory Limited, and the handling of company funds [3].

Core Viewpoint - Clear Medical (01406) is facing a lawsuit initiated by former executive director Xie Weiye, with the case number HCMP 1627/2025, filed in the Hong Kong High Court on September 19, 2025 [1] Group 1 - The lawsuit involves a request for the court to approve Xie Weiye to represent the company in litigation against seven potential defendants, including current and former executive directors and an advisory firm [2] - The plaintiff is also seeking the appointment of a receiver and manager for the company until the court decides on the proposed litigation [2] - Additionally, the plaintiff requests an independent investigation into the company's financial status and related circumstances, with a report to be submitted to the court [2] Group 2 - The proposed litigation by the plaintiff includes issues related to the acquisition of shares by Innovative Vision Inc, executive compensation, agreements with United Orion Advisory Limited, and the management of company funds [3] - Other matters for potential litigation involve the transfer of a debt of HKD 1.75 million (plus interest) from the plaintiff to a wholly-owned subsidiary, as well as the responsibilities of the potential defendants regarding the plaintiff's removal as a director [3] - The lawsuit also questions the validity of the board's decision to remove the plaintiff's directorship and the fiduciary duties of the potential defendants as current or former directors [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CLARITY MEDICAL GROUP HOLDING LIMITED 清晰醫療集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1406） 於二零二五年九月二十三日舉行之股東特別大會之投票表決結果 董事會欣然宣佈，通告所載之普通決議案已於二零二五年九月二十三日舉行之 股東特別大會上獲股東以投票表決方式正式通過。 | | | 票數 | | | --- | --- | --- | --- | | | 普通決議案 | （概約百分比） | | | | | 贊成 | 反對 | | 1. | 根據本公司組織章程細則（「細則」）第83(5) | 223,993,726 | 126,668,380 | | | 條罷免謝偉業醫生（「謝醫生」）作為本公司 | (63.88%) | (36.12%) | | | 執行董事的職務，此舉並不影響董事會根 | | | | | 據細則第86(4)條所作的釐定（即其 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CLARITY MEDICAL GROUP HOLDING LIMITED 清晰醫療集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1406） 內幕消息 涉及本公司、若干現任董事及一名前董事的法院申請 本公告乃由清晰醫療集團控股有限公司（「本公司」）的董事（「董事」）會（「董事 會」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港 法例第571章證券及期貨條例第XIVA部項下之內幕消息條文（定義見上市規則）作 出。 於二零二五年九月二十二日，本公司作為被告，接獲由原告謝偉業（「原告」）於香 港高等法院原訟法庭（「法院」）針對本公司發出的日期為二零二五年九月十九日之 原訴傳票（「原訴傳票」），案件編號為HCMP 1627/2025。原告為前執行董事，其 職務已於二零二五年八月一日經董事會根據本公司組織章程細則第86(4)條所載之 取消資格事件被撤消，且原告亦於二 ...

于本公告日期，公司及任何董事均未接获由谢伟业医生提起的任何正式法律程序，此事实进一步印证谢 伟业医生的指控缺乏实质依据。 为保障股东权益，公司坚决反对一切毫无根据的诋毁行为，并保留对任何恶意且无端诽谤公司者采取法 律行动的权利。 清晰医疗(01406)公布，公司近期持续通过各种渠道遭受诋毁公司声誉的无端企图，包括引用谢伟业医 生对公司及其若干董事的指控。谢伟业医生为前执行董事，惟诚如公司于2025年8月1日所公布，公司董 事会已于2025年8月1日撤销其职位。谢医生所涉指控事项，早前已于公司2025年5月30日的公告中披 露。 ...

Core Viewpoint - The company, Clear Medical (01406), is facing baseless attempts to tarnish its reputation through various channels, including allegations made by former executive director Dr. Xie Weiye [1] Summary by Relevant Sections - **Company's Response to Allegations** - The company has firmly opposed all unfounded defamatory actions and reserves the right to take legal action against any malicious and baseless defamers [1] - **Details on Dr. Xie Weiye's Allegations** - Dr. Xie Weiye's allegations against the company and several of its directors were previously disclosed in the company's announcement on May 30, 2025 [1] - As of the announcement date, neither the company nor any of its directors have received any formal legal proceedings initiated by Dr. Xie, further indicating the lack of substantive basis for his claims [1] - **Corporate Governance** - Dr. Xie Weiye's position as an executive director was revoked by the company's board on August 1, 2025 [1]